✦ LIBER ✦

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

✍ Scribed by Nancy U. Lin, Eric P. Winer, Duncan Wheatley, Lisa A. Carey, Stephen Houston, David Mendelson, Pamela Munster, Laurie Frakes, Steve Kelly, Agustin A. Garcia, Susan Cleator, Martina Uttenreuther-Fischer, Hilary Jones, Sven Wind, Richard Vinisko, et al

Book ID: 113062446
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 218 KB
Volume: 133
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-012-2003-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

9007 ORAL Phase II Study of Afatinib (BI

9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC

✍ Finocchiaro, G.; Santoro, A.; Grossi, F.; Bidoli, P.; Favaretto, A.; Clementi, L 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 59 KB

A Phase II Study of Weekly Vinorelbine a

A Phase II Study of Weekly Vinorelbine and Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer

✍ Juan Lucas Bayo-Calero; José I. Mayordomo; Pedro Sánchez-Rovira; Ramón Pérez-Car 📂 Article 📅 2008 🏛 CIG Media Group, LP. 🌐 English ⚖ 97 KB

A phase II trial of trastuzumab plus wee

A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial

✍ Stacy Moulder; Hailun Li; Molin Wang; William J. Gradishar; Edith A. Perez; Jose 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 250 KB

Results of a phase II study of liposomal

Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)

✍ J Baselga; M.A Climent; A Lluch; J Hornedo; P Gascon; A.T Sanchez; V Guillem; H 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 173 KB